Answers are grounded in this paper and cite their sources.
e18006 Background: Immunotherapy (IO) has emerged as the standard of care for recurrent and metastatic HNSCC. However, conventional PD-L1 expression levels offer limited utility for predicting therapeutic response. This study evaluates the application of a deep-learning framework, ENLIGHT-DP, to predict response to IO in HNSCC directly from common H&E slide scans. Methods: IO efficacy and pre-treatment tumor H&E slides were retrospectively collected from 113 HNSCC cases seen between 2020 and 2025 at the Taipei Veterans General Hospital (VGHTPE). On this data we trained, in cross-validation, an attention-based deep-learning model (ENLIGHT-DP) to predict a continuous response score to IO - the ENLIGHT Matching Score (EMS). For clinical practice, we also categorized all patients into three prediction classes: “EMS- H” (top 30% EMS), “EMS-I” (middle 40%) and “EMS-L” (bottom 30%). We defined "PDL1-I" as CPS 1-19, TC 1-9 if CPS is missing, and TPS 1-45 if both are missing. “PDL1-L” and “PDL1-H” were defined by values below and above these thresholds, respectively. Finally, we validated the model on two previously published cohorts collected at Hadassah Medical Center (HMC, n=25) and the BIO2 study from UHN, Toronto (BIO2, n=15). Results: The VGHTPE cohort had a median age of 57.8 years, with 90% males. Primary site distribution was 55% oral cavity, 17% oropharynx (5/19 cases HPV-associated), 15% hypopharynx, 8% larynx, 4% others. 15% of the cases were stage I/II, 9% stage III, 76% stage IV. 85% of cases had received prior radiation therapy, 48% had locoregional disease only, and 55% were treatment-naïve for the recurrent/metastatic disease. The cohort had an ORR of 34.5%, PFS of 5.6 months (3.3-7.9), and OS of 28.1 months (12.7-43.4). The EMS-H group had an ORR of 52.5%, 37% higher than the baseline. The EMS-I group had an ORR of 33.3%, and the EMS-L group 17.5%, 49.3% lower than baseline. The 35% ORR difference between EMS-H and EMS-L more than doubled the 16.3% ORR difference between PDL1-H and PDL1-L (41.3% and 25% respectively). ENLIGHT-DP achieved good stratification of the patient population with respect to PFS (HR: 0.447, p=0.005 for EMS-H vs. rest; HR: 0.343, p=0.0003 for EMS-H vs. EMS-L). This is superior to the PFS separation using PD-L1 (HR: 0.69, p=0.14 for PDL1-H vs. rest; HR: 0.523, p=0.0055 for PDL1-H vs. PDL1-L). ENLIGHT-DP was also borderline significant in stratifying with respect to OS (HR:0.55 , p=0.07 for EMS-H vs rest; HR: 0.577, p=0.16 for EMS-H vs. EMS-L), while PD-L1 was not predictive of OS (HR: 1.12, p=0.71 for PDL1-H vs. rest; HR: 1.1, p = 0.8 for PDL1-H vs PDL1-L). ENLIGHT-DP generalizes to the external cohorts with a ROC AUC of 0.70 in the HMC cohort and 0.67 in the BIO2 cohort, vs. 0.68 in the VGHTPE cohort. Conclusions: ENLIGHT-DP demonstrated a superior prediction performance to IO ORR, PFS, and OS in HNSCC, suggesting a potential clinical utility for treatment guidance.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: